Epigenomics AG (FRA:ECX) Tariff Resilience Score: 0/10 (As of Jul. 04, 2026)


FRA:ECX Epigenomics AG FRA:ECX
11 GF Score
Price €1.40
GF Value €0.09
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Epigenomics AG Tariff Resilience Score?

Epigenomics AG has the Tariff Resilience Score of 0, which implies that the company might have .

Epigenomics AG has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Epigenomics AG might have .

Epigenomics AG  (FRA:ECX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Epigenomics AG Tariff Resilience Score Related Terms

FRA:ECX
11GF Score
Epigenomics AG FRA:ECX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Epigenomics AG (FRA:ECX) Overvalued in 2026?

Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued. The current stock price of €1.40 is trading 1455.6% above its estimated GF Value™ of €0.09. GuruFocus considers Epigenomics AG to be Significantly Overvalued.

Key valuation signals for FRA:ECX:

  • Tariff Resilience Score: 0
  • GF Value™: €0.09 vs. price of €1.40 (1455.6% above fair value)
  • GF Score™: 11/100 with 3 warning signs

No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Epigenomics AG Business Description

Other Exchanges ECX:Germany
Address Ziegelhauser Landstrabe 3, Heidelberg, BW, DEU, 69120
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
11GF Score

Get the complete analysis for FRA:ECX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.40
Price
€0.09
GF Value